search
Back to results

Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa (BT-ASMN)

Primary Purpose

Severe Persistent Asthma

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
catheter ALAIR
Sponsored by
Arcispedale Santa Maria Nuova-IRCCS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Severe Persistent Asthma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient with severe persistent asthma uncontrolled found in stable for at least 3 weeks
  2. Patient receiving regular treatment with inhaled corticosteroids (beclomethason> 1000 mcg or equivalent) and LABA (salmeterol> = 100 mcg or equivalent)
  3. AQLQ score <6.25
  4. FEV1> = 60% predicted
  5. Patients not smoking for at least one year

Exclusion Criteria:

  1. acute asthma with life threatening
  2. concomitant respiratory diseases (eg, COPD or emphysema)
  3. use of ß-blocker drugs
  4. severe active infection in the last 2 weeks
  5. Pacemaker, internal defibrillator or other implanted electronic device.
  6. Known sensitivity to medications used to perform bronchoscopy, including lidocaine, atropine and benzodiazepines.
  7. Currently known bleeding disorder is not well controlled.
  8. Inability to stop prior to the procedure taking anticoagulants, antiplatelet agents, aspirin or non-steroidal anti-inflammatory drugs
  9. 18 years
  10. Pregnant women

Sites / Locations

  • REGGIO EMILIA IRCCS, Santa Maria Nuova HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Bronchial Thermoplasty

Arm Description

bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma

Outcomes

Primary Outcome Measures

analysis of the risk and benefit profile with questionnaire ACT and AQLQ
Evaluation of symptom control through the questionnaire ACT (ASTHMA CONTROL TEST) and AQLQ (Asthma quality life Questionaire) according to GINA criteria. The questionnaires AQLQ and ACT will be collected 3 months before the TB, the day before the procedure, and 3, 6, 12 months after the end of the procedure.

Secondary Outcome Measures

Analyze the changes in the state of innervation and nerve receptors before and after BT on histological samples of the bronchial mucosa
first biopsies in left lower lobe non yet treated; second biopsies in right lower lobe already treated; third biopsies in upper lobe already treated;

Full Information

First Posted
April 2, 2013
Last Updated
March 31, 2014
Sponsor
Arcispedale Santa Maria Nuova-IRCCS
search

1. Study Identification

Unique Protocol Identification Number
NCT01839591
Brief Title
Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa
Acronym
BT-ASMN
Official Title
Treatment of Bronchial Severe Asthma With Bronchial Thermoplasty. Assessment of Efficacy and Safety of Treatment, Study of Effects on Neuronal and Chemosensitive Component of the Bronchial Mucosa Pre and Post Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
March 2014
Overall Recruitment Status
Unknown status
Study Start Date
March 2013 (undefined)
Primary Completion Date
April 2015 (Anticipated)
Study Completion Date
December 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Arcispedale Santa Maria Nuova-IRCCS

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In severe bronchial asthma the mechanism of inflammation and bronchospasm is complex and still not clarified. The smooth muscle cells play an important role from the mechanical point of view, as a culmination of neurogenic stimuli and inflammatory cytokines that determine as final effect the bronchospasm and over time a hypertrophy of the muscular coat. There are some other hypothesis that the smooth muscle cells may play a role as central regulator of chemical mediators that cause bronchospasm and inflammation, although there are currently no firm conclusions 2 According to other studies3,the nerve receptors TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 1 have a great importance in the complex mechanism of airway inflammation too. (There are at least 4) These receptors would intervene according to the following mechanism: Irritants on the bronchial mucosa stimulate the TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 1 present on afferent endings of sensory fibers, unmyelinated C (chemiosensitive neurons) On the same afferent axon acting factors with the activation effect (lowering the activation threshold, increase the expression, promote the translocation of TRPV1 receptor on the membrane). Among these factors the neurotrophins of which the most important NERVE GROWTH FACTOR (NGF) The activation of TRPV1 (through release of Ca2 + +) determines two efferent responses: CENTRALLY-MEDIATED LOCAL AXON Reflex Investigators hypothesized that BT may have a strong influence on the destruction of nerve receptors TRPV1 and unmyelinated nerve fibers located in the mucosa going to stop reflections both central and local authorities responsible for the activation of bronchospasm. In support of this hypothesis, there are some anatomical studies4, which show that these receptors are more numerous at the level of main bronchi which are the main target of BT. Please note in this context that it is already known that in thermoablations commonly used in cardiology it is used a radio frequency with development of heat controlled to 65 °, as in the BT, able to interrupt the circuit nervous responsible for the activation of the circuit causing the abnormal 'arrhythmia.
Detailed Description
The mechanism of action the bronchial thermoplasty exerts the positive action demonstrated by the studies through is not yet well understood yet. The only action on the denaturation and destruction of the smooth muscle layer of the bronchi at intermediate and high caliber perhaps not fully explain its action, taking into account that most of the smooth muscle loading of the small airways is minimally altered by the procedure. From the premises outlined in the section on the mechanism of inflammation we hypothesized that BT may have a strong influence on the destruction of nerve receptors TRPV1 and unmyelinated nerve fibers located in the mucosa going to stop reflections both central and local authorities responsible for the activation of bronchospasm. In support of this hypothesis, there are some anatomical studies4, which show that these receptors are more numerous at the level of main bronchi which are the main target of BT. Please note in this context that it is already known that in thermoablations commonly used in cardiology it is used a radio frequency with development of heat controlled to 65 °, as in the BT, able to interrupt the circuit nervous responsible for the activation of the circuit causing the abnormal 'arrhythmia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Persistent Asthma

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bronchial Thermoplasty
Arm Type
Experimental
Arm Description
bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
Intervention Type
Device
Intervention Name(s)
catheter ALAIR
Other Intervention Name(s)
Catheter ALAIR Boston Scientific, M005ATS25010 MOd ATS 2-5
Intervention Description
Catheter ALAIR Radiofrequency 65°
Primary Outcome Measure Information:
Title
analysis of the risk and benefit profile with questionnaire ACT and AQLQ
Description
Evaluation of symptom control through the questionnaire ACT (ASTHMA CONTROL TEST) and AQLQ (Asthma quality life Questionaire) according to GINA criteria. The questionnaires AQLQ and ACT will be collected 3 months before the TB, the day before the procedure, and 3, 6, 12 months after the end of the procedure.
Time Frame
Change from Baseline in ACT and AQLQ Questionaire one year after the end of the procedure
Secondary Outcome Measure Information:
Title
Analyze the changes in the state of innervation and nerve receptors before and after BT on histological samples of the bronchial mucosa
Description
first biopsies in left lower lobe non yet treated; second biopsies in right lower lobe already treated; third biopsies in upper lobe already treated;
Time Frame
biopsies every 4 weeks( during the treatment)
Other Pre-specified Outcome Measures:
Title
Evaluate the effect of BT on the run neurogenic inflammation by analysis of the chemical mediators of inflammation on histological samples of the bronchial mucosa.
Description
first biopsies in left lower lobe non yet treated; second biopsies in right lower lobe already treated; third biopsies in upper lobe already treated;
Time Frame
biopsies every 4 weeks (during the treatment)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with severe persistent asthma uncontrolled found in stable for at least 3 weeks Patient receiving regular treatment with inhaled corticosteroids (beclomethason> 1000 mcg or equivalent) and LABA (salmeterol> = 100 mcg or equivalent) AQLQ score <6.25 FEV1> = 60% predicted Patients not smoking for at least one year Exclusion Criteria: acute asthma with life threatening concomitant respiratory diseases (eg, COPD or emphysema) use of ß-blocker drugs severe active infection in the last 2 weeks Pacemaker, internal defibrillator or other implanted electronic device. Known sensitivity to medications used to perform bronchoscopy, including lidocaine, atropine and benzodiazepines. Currently known bleeding disorder is not well controlled. Inability to stop prior to the procedure taking anticoagulants, antiplatelet agents, aspirin or non-steroidal anti-inflammatory drugs 18 years Pregnant women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicola Facciolongo NF Facciolongo, M D
Phone
0522-295956
Ext
+39
Email
nicola.facciolongo@asmn.re.it
First Name & Middle Initial & Last Name or Official Title & Degree
Carla CG Galeone, phD
Email
carla.galeone@asmn.re.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicola NF Facciolongo, M.D.
Official's Role
Principal Investigator
Facility Information:
Facility Name
REGGIO EMILIA IRCCS, Santa Maria Nuova Hospital
City
Reggio Emilia
ZIP/Postal Code
42024
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicola NF Facciolongo, MD
Phone
0522-295956
Ext
+39
Email
nicola.facciolongo@asmn.re.it
First Name & Middle Initial & Last Name & Degree
Nicola NF Facciolongo, MD
First Name & Middle Initial & Last Name & Degree
Roberto RP Piro, MD
First Name & Middle Initial & Last Name & Degree
Gianluigi GB Bajocchi, MD
First Name & Middle Initial & Last Name & Degree
Francesco FM Menzella, MD
First Name & Middle Initial & Last Name & Degree
Claudia CC Castagnetti, MD
First Name & Middle Initial & Last Name & Degree
Alberto AC Cavazza, MD
First Name & Middle Initial & Last Name & Degree
Vladimiro VP Pietrini, MD
First Name & Middle Initial & Last Name & Degree
Luisa LS Savoldi, Statistics
First Name & Middle Initial & Last Name & Degree
Carla CG Galeone, Biologist

12. IPD Sharing Statement

Citations:
PubMed Identifier
29422039
Citation
Facciolongo N, Di Stefano A, Pietrini V, Galeone C, Bellanova F, Menzella F, Scichilone N, Piro R, Bajocchi GL, Balbi B, Agostini L, Salsi PP, Formisano D, Lusuardi M. Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma. BMC Pulm Med. 2018 Feb 8;18(1):29. doi: 10.1186/s12890-017-0554-8.
Results Reference
derived

Learn more about this trial

Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa

We'll reach out to this number within 24 hrs